Harrow, Inc. announced the launch of its 'Harrow Cares' program through a strategic partnership with Cencora. This initiative provides a comprehensive suite of access and affordability services designed to support retina specialists, their staff, and patients in utilizing IHEEZO and TRIESENCE.
The program leverages a patient support services hub to ensure seamless enrollment, rapid access to therapy, and personalized support. Cencora, a global leader in pharmaceutical solutions, offers services ranging from real-time benefit verifications to flexible affordability options and product assurance programs.
Mark L. Baum, CEO of Harrow, emphasized that the partnership reflects a shared commitment to ensuring life-changing medications are accessible and affordable. This initiative underscores Harrow's strategic focus on expanding and solidifying its presence in the U.S. retina market, a key area of growth and innovation for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.